In the realm of drug development, small-molecule inhibitors and antibody drugs are being designed to specifically block NLRC3 activity, thereby activating the cGAS-STING pathway and potentiating anti-tumor immune responses 64, 94. This evidence concerns the gene STING1 and neoplasm.